ATYR
aTYR PHARMA INC
Key Financials
Revenue
$190000
↓ 19.1%
Operating Income
$-77627000
↓ 14.3%
Net Income
$-74118000
↓ 15.8%
EPS (Diluted)
$-0.80
↑ 7.0%
Total Assets
$93.0M
↓ 4.0%
Cash & Equivalents
$10.7M
↓ 2.8%
Shareholders' Equity
$67.5M
↓ 3.6%
Long-term Debt
$8.3M
0.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| S-8 | 8/7/2026 | View on SEC |
| 10-Q | 8/7/2026 | View on SEC |
| 8-K | 8/7/2026 | View on SEC |
| SCHEDULE 13G/A | 8/6/2026 | View on SEC |
| 8-K | 7/31/2026 | View on SEC |
| SCHEDULE 13G/A | 7/27/2026 | View on SEC |
| SCHEDULE 13G/A | 7/8/2026 | View on SEC |
| 8-K | 6/8/2026 | View on SEC |
| SCHEDULE 13G/A | 6/5/2026 | View on SEC |
| 8-K | 6/1/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ATYR |
| Company Name | aTYR PHARMA INC |
| CIK | 1339970 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 8587318389 |